Dermata Therapeutics (DRMA) Receivables - Accured (2022 - 2023)
Dermata Therapeutics (DRMA) posted quarterly Receivables - Accured of $8356.0 for Q4 2023, down 33.69% year-over-year from $12602.0 in Q4 2022, and up 10894.74% quarter-over-quarter from $76.0 in Q3 2023.
Dermata Therapeutics (DRMA) Receivables - Accured (2022 - 2023) Analysis & Trends
Dermata Therapeutics' Receivables - Accured history runs 2 years deep, the most recent figure standing at $8356.0 for Q4 2023.
- In Q4 2023, Receivables - Accured fell 33.69% year-over-year to $8356.0; the TTM figure through Dec 2023 stood at $8356.0 (down 33.69% YoY), while the FY2023 annual figure was $8356.0, down 33.69% from the prior year.
- Receivables - Accured for Q4 2023 stood at $8356.0, up from $76.0 in the prior quarter.
- The five-year high for Receivables - Accured was $12893.0 in Q3 2022, with the low at $76.0 in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables - Accured (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.84 Bn | 131.99 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.48 Bn | 78.49 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn | - |
| 4 | Moderna | 60.15 Bn | 55.01 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 42.22 Bn | 37.12 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.54 Bn | 10.14 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.22 Bn | 26.38 Bn | - | - |
| 10 | Dermata Therapeutics | 5.60 Mn | 5.60 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 8,356.00 |
| Dec 31, 2023 | 8,356.00 |
| Sep 30, 2023 | 76.00 |
| Sep 30, 2023 | 76.00 |
| Jun 30, 2023 | 790.00 |
| Jun 30, 2023 | 790.00 |
| Mar 31, 2023 | 6,358.00 |
| Mar 31, 2023 | 6,358.00 |
| Dec 31, 2022 | 12,602.00 |
| Dec 31, 2022 | 12,602.00 |
| Sep 30, 2022 | 12,893.00 |
| Sep 30, 2022 | 12,893.00 |